Tacrolimus + Tacrolimus
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Graft Rejection
Conditions
Acute Graft Rejection, Diabetes
Trial Timeline
Jun 24, 2011 → Oct 11, 2019
NCT ID
NCT01265537About Tacrolimus + Tacrolimus
Tacrolimus + Tacrolimus is a pre-clinical stage product being developed by Astellas Pharma for Acute Graft Rejection. The current trial status is completed. This product is registered under clinical trial identifier NCT01265537. Target conditions include Acute Graft Rejection, Diabetes.
What happened to similar drugs?
20 of 20 similar drugs in Acute Graft Rejection were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01265537 | Pre-clinical | Completed |
Competing Products
20 competing products in Acute Graft Rejection